[ad_1]
With the American pharmaceutical company Moderna, another relevant manufacturer for Europe has presented relevant data for its corona vaccine. The RNA vaccine was 94.5 percent effective, it said in a Moderna statement Monday. According to its own information, the EU Commission is currently negotiating with the US company the delivery of up to 160 million doses of vaccine. A contract has not yet been concluded.
The phase III study of the Moderna vaccine, of which the first results have already been published, comprises a total of 30,000 subjects. Half of them received the vaccine, the other half acted as a control group and received a placebo. A total of 95 study participants have contracted Covid-19 so far. Of these, only 5 cases were vaccinated subjects, 90 cases were diagnosed in the control group. This results in an effectiveness of 94.5 percent.
However, it is only a question of how far the vaccine can prevent real diseases. Data on the degree to which the vaccine prevents infections, including infections without symptoms of disease, are still lacking. For complete vaccination protection, two doses are required at intervals.
Approval process in the US and Europe
Also on Monday it emerged that the European Medicines Agency Ema is initiating a so-called continuous review process for the Moderna vaccine, which aims to achieve comparatively quick approval. Moderna also plans to apply for emergency approval from the US pharmaceutical agency FDA in the coming weeks.
Meanwhile, the group is continually evaluating more data from the study. Based on its own information, the company expects to receive emergency approval in the US based on a final analysis with 151 cases of infection among study participants.
The Modern preparation with the name mRNA-1273 is one of the so-called RNA vaccines. The remedy contains genetic information about the pathogen, from which the body produces a viral protein. The goal of vaccination is to stimulate the immune system to produce antibodies against this protein. This allows you to react faster if someone actually comes into contact with Sars-CoV-2.
Moderna says it will be ready by the end of the year to deliver about 20 million doses of vaccines to the US if approved. Up to 1 billion cans are expected to be made in the next year.
Other countries like Russia, China and Bahrain are already one step further and have launched the first vaccines with restrictions. Parts of the population are already vaccinated with it. How well these agents actually protect and what side effects they may have is currently largely open.
